Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
12.06. | ALX Oncology berichtet über Ergebnisse der Jahreshauptversammlung | 4 | Investing.com Deutsch | ||
ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
12.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
27.05. | H.C. Wainwright maintains ALX Oncology stock Buy rating | 3 | Investing.com | ||
20.05. | ALX Oncology Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event | 136 | GlobeNewswire (Europe) | - A potential best- and first-in-class antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors, ALX2004 is uniquely designed with every component optimized to maximize the... ► Artikel lesen | |
13.05. | ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 | 3 | GlobeNewswire (USA) | ||
08.05. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | 2 | SEC Filings | ||
08.05. | ALX Oncology GAAP EPS of -$0.58 misses by $0.10 | 1 | Seeking Alpha | ||
08.05. | ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update | 304 | GlobeNewswire (Europe) | Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase... ► Artikel lesen | |
08.05. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 2 | SEC Filings | ||
07.05. | What's Next: ALX Oncology Holdings' Earnings Preview | 1 | Benzinga.com | ||
02.05. | ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | 3 | GlobeNewswire (USA) | ||
25.04. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 2 | SEC Filings | ||
25.04. | ALX Oncology doubles down on lead CD47 inhibitor after asset fails two midstage cancer trials | 1 | FierceBiotech | ||
25.04. | ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma | 175 | GlobeNewswire (Europe) | - Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology's investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and demonstrated... ► Artikel lesen | |
25.04. | ALX Oncology falls on mid-stage trial setback for lead asset | 1 | Seeking Alpha | ||
25.04. | ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evaluating Evorpacept with a Checkpoint Inhibitor for the Treatment of Head and Neck Cancers Did Not Meet Primary Endpoints | 197 | GlobeNewswire (Europe) | In ASPEN-03 and ASPEN-04 trials, efficacy data do not support advancing evorpacept in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), into a registrational studyCompany remains... ► Artikel lesen | |
08.04. | ALX Oncology's ALX2004 gains FDA IND clearance to treat solid tumours | 1 | Pharmaceutical Business Review | ||
07.04. | ALX Oncology gets FDA clearance to begin trial of ALX2004 | 3 | Seeking Alpha | ||
07.04. | ALX Oncology bringt neues Krebsmedikament in Phase-1-Studien | 2 | Investing.com Deutsch | ||
07.04. | ALX Oncology advances new cancer drug into Phase 1 trials | 2 | Investing.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
EVOTEC | 7,138 | -0,81 % | Deutz Aktie: Vorsicht, es wird kritisch! - Dazu: Allianz, Evotec, Kontron, Mutares, TUI - 4investors Aktien Top-News | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
MODERNA | 23,305 | +0,17 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
NOVAVAX | 5,424 | -0,40 % | Novavax Aktie: Sondermeldung sorgt für starke Verunsicherung. Das ist der Grund und so müssen Anleger heute handeln! | ||
CRISPR THERAPEUTICS | 40,600 | 0,00 % | CRISPR Therapeutics AG: CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310 Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline | -New Phase 1 clinical data for CTX310 continues to demonstrate dose-dependent reductions in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 86%... ► Artikel lesen | |
INOVIO PHARMACEUTICALS | 1,840 | +1,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
INTELLIA THERAPEUTICS | 8,366 | +2,50 % | CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential? | ||
DEFENCE THERAPEUTICS | 0,470 | +2,17 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
EDITAS MEDICINE | 1,924 | -1,00 % | Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now? | ||
SAREPTA THERAPEUTICS | 14,575 | -0,21 % | Did The FDA Make A Mistake? Sarepta's Elevidys Approval Under Scrutiny | ||
BIOMARIN PHARMACEUTICAL | 47,060 | -0,17 % | BioMarin Presents Long-term Efficacy And Safety Of Roctavian | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) Tuesday announced new data underscoring the long-term efficacy and safety of Roctavian (valoctocogene roxaparvovec-rvox).The Phase... ► Artikel lesen | |
EXELIXIS | 37,080 | -0,59 % | ROUNDUP/Aktien New York: Entspannt nach US-Militärschlag und positiven Daten | NEW YORK (dpa-AFX) - Angesichts der bislang überschaubaren ökonomischen Auswirkungen des US-Militärschlags gegen den Iran sind die Anleger an den US-Börsen am Montag recht gelassen geblieben. Zudem... ► Artikel lesen | |
PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -0,67 % | Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock | ||
VAXART | 0,433 | +2,90 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
NEUROCRINE BIOSCIENCES | 108,55 | +1,26 % | Neurocrine Biosciences, Inc.: Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive ... | Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia
Findings... ► Artikel lesen | |
EXACT SCIENCES | 46,740 | +1,95 % | Exas, Guardant, Gilead among gainers as Supreme Court ensures free preventive care |